Search

everythinglearnresearchcommunity

for

Search:↓

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

The laser comb did not improve hair regrowth in mice with alopecia areata.

Light therapy can effectively treat vitiligo and hair loss caused by a specific medication.

Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.

Leflunomide is more likely to help treat alopecia areata than cause it.

T cells and bacteria in the gut and skin help maintain health and protect against disease.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Finasteride helps female-pattern hair loss.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Lichen planus is a skin condition that can resolve on its own, is linked to hepatitis C, and increases the risk of skin cancer.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Psoriasis skin changes are complex and might need several biopsies for a clear diagnosis.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Older skin has higher cancer risk due to inflammation and stem cell issues.

HIV can cause unusual and severe skin problems that are hard to treat.

Alopecia Areata has no guaranteed treatment for hair regrowth, but options like corticosteroids and minoxidil are used, with future research focusing on genetic and immune therapies.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.

Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.

Recognizing the different stages of alopecia areata is crucial for accurate diagnosis and treatment.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

People with alopecia areata often have lower vitamin D levels and more inflammation, suggesting vitamin D might be involved in the condition.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.